This study investigated expression of serum miR-27b and miR-451 in patients with congenital heart disease associated pulmonary arterial hypertension (CHDPAH), and analyzed the risk factors of CHDPAH. A total of 114 patients with CHD admitted to the First Affiliated Hospital
of the University of South China were recruited and allocated into a study group (61 patients with PAH) and a control group (53 patients without PAH). Reverse transcriptionpolymerase chain reaction (RTPCR) was employed for the qualification of serum miR27b and miR451, and an
automatic biochemical analyzer was used for the measurement of biochemical indexes in peripheral blood, and enzymelinked immunosorbent assay (ELISA) for the detection of serum brain natriuretic peptide (BNP) and asymmetric dimethylarginine (ADMA). The patients with CHDPAH showed
higher serum miR27b, BNP and ADMA but lower miR451 than the controls. Serum miR27b was positively correlated with mean pulmonary artery pressure (mPAP), BNP and ADMA, whereas serum miR451 was negatively correlated with them. The combined detection of miR27b and miR451 was more valuable
than a single detection in the diagnosis of CHDPAH. Logistic regression analysis showed that ADMA, miR27b, miR451 and ventricular septal defect (VSD) were independent risk factors for CHDPAH. In conclusion, miR27b is highly expressed and miR451 and the expression is low in patients with
CHDPAH. miR27b and miR451 are significantly correlated with BNP, ADMA, and the severity of the disease. The combination of miR27b and miR451 has high diagnostic value and can be used as a biomarker for the diagnosis and assessment of CHDPAH. CHDPAH is common in children with CHD, which poses
a serious threat to the life and safety. At present, there are no effective methods for its early diagnosis and treatment. MicroRNAs (miRNAs, miRs) have been found to be closely related to the pathogenesis of CHDPAH. In this study, miR27b and miR451 with differential expression in CHDPAH were
evaluated, and it was found that they were of great significance in the diagnosis and assessment of CHDPAH.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Paediatric Intensive Care Unit, The First Affiliated Hospital of the University of South China, Hengyang, Hunan 421000, P.R. China
Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan 410007, P.R. China
Department of Pediatrics, The First Affiliated Hospital of the University of South China, Hengyang, Hunan 421000, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites